Antibody Discovery

Single Plasma cell INterrogation®

High-throughput screening enables interrogation of the natural antibody repertoire. Our patented SPIN® platform uses microfluidic technology to isolate antigen-specific plasma cells delivering antibodies with higher affinity and specificity.

Learn more about SPIN®

Products

Exonbio is committed to developing best-in-class in-vitro diagnostics antibodies to help alleviate the global burden of infectious diseases.

covid 19 antibodies

SARS-CoV-2

Enveloped virus having a positive single-stranded RNA genome and pathogenic

Flu B Antibodies

Influenza B

Eight segments of linear negative-sense, single-stranded RNA

Ebola

Ebola

Negative-sense, non-segmented single-stranded linear RNA genome about 18-19 kb in size

Streptococcus Pneumonia

Streptococcus Pneumonia

Lancet-shaped, gram-positive, facultative anaerobic bacteria with more than 100 known serotypes

Flu A Antibodies

Influenza A

Eight single RNA segments with two major glycoproteins hemagglutinin and neuraminidase

RSV Antibodies

RSV

Single-stranded RNA virus of the family Paramyxoviridae

Tuberculosis

M. Tuberculosis

Aerobic, non-motile, gram-positive, and non-spore-forming rod-shaped bacillus

Services

Exonbio provides customers access to SPIN® platform with streamlined procedures for immunizations, screening, characterization, sequencing, purification, and recombinant production.

Technology

Patented SPIN® Technology

High-throughput screening has enabled interrogation of the natural antibody repertoire. Our proprietary Single Plasma Cell Interrogation (SPIN®) platform uses microfluidic technology to isolate antigen-specific plasma cells and single-cell technology to analyze native paired antibody genes.

High affinity: High affinity antibodies are selected owing to the isolation of the terminal differentiated plasma cells

Broad spectrum of epitope coverage: Unique properties of the rabbit immune system allows to obtain antibodies against a broad spectrum of epitopes for a single antigen